Probiotic Supplementation IN NAFLD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-12

Study Completion Date

2023-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

this study aimed to evaluate the effectiveness of Probiotics supplementation (lactobacillus) on NAFLD fibrosis score.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation

NCT05402449

Non-Alcoholic Fatty Liver Disease

COMPLETED NA

Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH

NCT04555434

Non-Alcoholic Fatty Liver Disease

UNKNOWN NA

The Effect of Probiotics on the Clinical Outcomes and Gut Microenvironment in Patients With Fatty Liver

NCT04074889

Non-Alcoholic Fatty Liver Disease

UNKNOWN NA

Probiotics for the Prevention of Major Complications of Cirrhosis

NCT00312910

Liver Cirrhosis

COMPLETED NA

Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management

NCT04823676

Non Alcoholic Fatty Liver

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by accumulation of fat (\> 5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. NAFLD can cause liver inflammation and progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular carcinoma (HCC).

The global prevalence of NAFLD in adults is estimated to be approximately 25%.The prevalence of NAFLD increases with increasing body mass index. in 2012 Chalasani et al, reported that 67% of overweight and 94% of obese individuals have NAFLD.

There is a consensus regarding increasing worldwide prevalence of NAFLD and its impact on health, especially the progression to liver cirrhosis and hepatocellular carcinoma. Longitudinal studies of NAFLD have reported an increase in all-cause mortality, cardiovascular mortality, and liver-related mortality , NAFLD carries a large economic burden and therefore poor health-related quality of life.

Lifestyle changes (diet and exercise) are the major and first suggestions of the guidelines ,as regard pharmaceutical interventions, agents with potential benefit in NASH include thiazolidinediones (TZDs), statins although they are well recognized in the treatment of dyslipidemia, their use as a specific treatment for NAFLD is not well evidenced.

There is some data suggest that disruptions in the gut microbiome may play a role in the pathogenesis of NAFLD and progressions to NASH.

A probiotic is a live microbial culture or cultured dairy product, which plays an important role in health. Probiotics for the treatment of NAFLD are seemingly a promising treatment option. Relatively easy availability, low cost, and absence of serious side effects make probiotics a lucrative choice.

liver biopsy remains the gold standard for NAFLD diagnosis but it is impractical as a diagnostic tool because it is invasive and expensive.

NAFLD fibrosis score constructed from routine clinical and laboratory variables can accurately predict the presence or absence of advanced fibrosis in NAFLD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

NAFLD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

probiotic group

Healthy lifestyle habits and standard diet was recommended for participants ,Probiotic supplementation (Lacteol fort 10 billion) which contains culture medium and lactobacillus LS as active ingredients was administered in the form of oral sachets once daily for 12 weeks.

Group Type EXPERIMENTAL

Control Test

Intervention Type DRUG

Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients

standard treatment group

Healthy lifestyle habits and standard diet was recommended for participants ,

Group Type ACTIVE_COMPARATOR

Control Test

Intervention Type DRUG

Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control Test

Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

standard treatment group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between18 and 60
* BMI ≥ 25 kg/m2
* Sonographic findings of NAFLD +/- elevated liver enzymes (not more than 2 folds increase).

Exclusion Criteria

* ▪ Any evidence of chronic liver diseases including viral hepatitis (B and C), auto immune hepatitis.

* History of alcohol drinking.
* Chronic medication use (drugs that cause elevated liver enzymes, recent antibiotic use or paracetamol use in the last month)
* Persistent elevation of liver enzymes for 3 months.
* History of DM.
* History of statin therapy for cardiovascular disease (CVD).
* History of recent operation.
* History of gastroenteritis or diarrhea in the last 2 week.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes